JP2017506505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506505A5 JP2017506505A5 JP2016549076A JP2016549076A JP2017506505A5 JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5 JP 2016549076 A JP2016549076 A JP 2016549076A JP 2016549076 A JP2016549076 A JP 2016549076A JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- seq
- agent according
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 66
- 102000003840 Opioid Receptors Human genes 0.000 claims description 24
- 108090000137 Opioid Receptors Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 4
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 4
- 102000016979 Other receptors Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007876 drug discovery Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000007781 signaling event Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101710122576 Isocitrate lyase 2 Proteins 0.000 claims 1
- 230000000707 stereoselective effect Effects 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933742P | 2014-01-30 | 2014-01-30 | |
| US61/933,742 | 2014-01-30 | ||
| PCT/EP2015/051991 WO2015121092A1 (en) | 2014-01-30 | 2015-01-30 | Opioid receptor binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506505A JP2017506505A (ja) | 2017-03-09 |
| JP2017506505A5 true JP2017506505A5 (enExample) | 2018-03-08 |
| JP6687525B2 JP6687525B2 (ja) | 2020-04-22 |
Family
ID=52434839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549076A Active JP6687525B2 (ja) | 2014-01-30 | 2015-01-30 | オピオイド受容体結合剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10233241B2 (enExample) |
| EP (1) | EP3099707B1 (enExample) |
| JP (1) | JP6687525B2 (enExample) |
| AU (1) | AU2015217846B2 (enExample) |
| CA (1) | CA2936728C (enExample) |
| WO (1) | WO2015121092A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| US10233241B2 (en) | 2014-01-30 | 2019-03-19 | Vib Vzw | Opioid receptor binding agents and uses thereof |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| US11668021B2 (en) | 2017-05-09 | 2023-06-06 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| US11505601B2 (en) | 2017-10-11 | 2022-11-22 | Nanjing Legend Biotech Co., Ltd | Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum |
| WO2020221769A1 (en) * | 2019-04-29 | 2020-11-05 | Confo Therapeutics N.V. | Screening methods and assays for use with transmembrane proteins, in particular with gpcrs |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
| WO2026057805A1 (en) * | 2024-09-12 | 2026-03-19 | Universite De Geneve | Peptidic opioid receptor antagonists and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5882944A (en) * | 1993-06-23 | 1999-03-16 | The Regents Of The University Of California | Methods for G protein coupled receptor activity screening |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
| DK1144616T4 (da) | 1999-01-19 | 2009-03-30 | Unilever Nv | Fremgangsmåde til fremstilling af antistoffragmenter |
| CA2370351A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| WO2001040310A2 (en) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| ATE513854T1 (de) | 2000-12-13 | 2011-07-15 | Bac Ip B V | Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
| CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2121757A2 (en) | 2007-02-21 | 2009-11-25 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| FR2916977A1 (fr) * | 2007-06-06 | 2008-12-12 | Engelhard Lyon Sa | STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE. |
| WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
| WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| EP2611826B1 (en) | 2010-08-30 | 2016-09-21 | Confometrx, Inc. | Method and composition for crystallizing a family c gpcr |
| US8765414B2 (en) | 2011-03-15 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same |
| EA201391514A1 (ru) | 2011-05-13 | 2014-08-29 | Рецептос, Инк | Новые партнеры слияния для кристаллизации рецепторов, связанных с g-белками |
| CN105102478A (zh) | 2013-01-30 | 2015-11-25 | 弗拉芒区生物技术研究所 | 用于筛选和药物发现目的的新型嵌合多肽 |
| US10233241B2 (en) | 2014-01-30 | 2019-03-19 | Vib Vzw | Opioid receptor binding agents and uses thereof |
-
2015
- 2015-01-30 US US15/115,621 patent/US10233241B2/en active Active
- 2015-01-30 AU AU2015217846A patent/AU2015217846B2/en active Active
- 2015-01-30 WO PCT/EP2015/051991 patent/WO2015121092A1/en not_active Ceased
- 2015-01-30 JP JP2016549076A patent/JP6687525B2/ja active Active
- 2015-01-30 CA CA2936728A patent/CA2936728C/en active Active
- 2015-01-30 EP EP15701821.9A patent/EP3099707B1/en active Active
-
2019
- 2019-03-15 US US16/355,442 patent/US11352422B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506505A5 (enExample) | ||
| RU2481355C2 (ru) | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей | |
| JP2023524733A (ja) | 遺伝子発現を活性化及びサイレンシングするためのエフェクタードメインの作出、同定及び性質決定のための組成物、システム及び方法 | |
| Naved et al. | Kidney repair and regeneration: perspectives of the NIDDK (Re) Building a Kidney consortium | |
| US7785808B2 (en) | Treatment of inflammation using α7 receptor-binding cholinergic agonists | |
| US11814426B2 (en) | Anti-tenascin C antibodies and uses thereof | |
| RU2013153592A (ru) | Анти-mif антитела | |
| JP6587609B2 (ja) | 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法 | |
| JP2013541335A5 (enExample) | ||
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| Li et al. | Preparation of a chicken scFv to analyze gentamicin residue in animal derived food products | |
| WO2008031133A3 (en) | Borrelia antigens | |
| RU2013123270A (ru) | Структуры слитого белка шелка пауков для связывания с органической мишенью | |
| Kuai et al. | Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β | |
| Yamashita et al. | Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice | |
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| CN111393529A (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| WO2022037527A1 (zh) | 结合bcma的单可变结构域及抗原结合分子 | |
| JP2014509860A5 (enExample) | ||
| WO2006116442A3 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| CN108290950B (zh) | 抗cd95l抗体 | |
| Hollingsworth et al. | Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants | |
| EP3992205A1 (en) | Sars coronavirus-2 spike protein binding compounds | |
| Cornish et al. | Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2 | |
| US20250012808A1 (en) | Parallel antibody engineering compositions and methods |